During AD progression, Aβ fragments and excitotoxic stimuli inhibit APC/C-Cdh1, leading to abnormal stabilization of PFKFB3, driving metabolic reprogramming and compromising the PPP’s antioxidant capacity (27–30). This evidence concerns the gene CDH1 and Alzheimer disease.